Resmed CDI (ASX:RMD)
ResMed Inc (ASX: RMD) is a United States based business that develops and manufactures medical devices to help people with sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed, which is short for Respiratory Medicine, was founded in 1989 by Dr Peter Farrell and now helps customers & patients in over 120 countries.
Resmed CDI (ASX:RMD) share price
Resmed CDI (ASX:RMD) passive income
Resmed CDI (ASX:RMD) share price news
Why the ResMed (ASX:RMD) share price is down 11% today
ResMed CDI (ASX: RMD) shares are trading down about -11% in early trade to ~$30 per share after its 4Q23 result came in below consensus expectations.
Why the Resmed (ASX: RMD) share price is charging higher today
The Resmed CDI (ASX:RMD) share price bounced 6.5% higher today following the release of its Q3 results. Resmed and CSL Limited (ASX:CSL) seem good value relative to Cochlear Limited (ASX:COH).
2 ASX healthcare shares to buy for defensive earnings (one big, one small)
Resmed CDI (ASX:RMD) shares and the Monash IVF Group Ltd (ASX:MVF) share price look very tempting at these prices, writes Seneca’s Luke Laretive.
LIVE ASX reports: CBA, TLS, IAG, AZJ, RMD, REA, GQG, NWS, AMP & DIS
LIVE ASX reporting season coverage is on The Australian Investors Podcast. Today Owen Rask & Drew Meredith cover Commonwealth Bank of Australia (ASX:CBA), AMP Limited (ASX:AMP), ResMed Inc (ASX:RMD) and more.
CRUNCHED: The ASX 200 is down, but it’s not out
On Wednesday, the Australian share market, or S&P/ASX 200 (INDEXASX: XJO) and All Ordinaries (ASX: XAO), hits its lowest level since 2020. Overnight, however, a firm 0.75% increase in US interest rates allowed the US stock market to bounce 1.5%.
3 key investor takeaways from the week
Here are my three key investor takeaways from a shortened week that saw the S&P/ASX 200 (ASX: XJO) finish broadly flat.
ASX 200 morning report – RHC, RIO & AGL shares in focus
The S&P/ASX 200 (ASX:XJO) finished flat on Wednesday as Ramsay Health Care (ASX:RHC) and Rio Tinto (ASX:RIO) shares were in the news.
ASX 200 morning report – PDL, IRE & ASX lithium shares in focus
It was another weak day for the S&P/ASX 200 (ASX: XJO) on Tuesday as Pendal (ASX:PDL) and Iress (ASX:IRE) shares made headlines.
Is it time to buy Cathie Wood’s beaten-up biotech companies (BATS:ARKG)?
Cathie Wood’s ARK Genomic Revolution ETF (BATS: ARKG) and ASX-listed biotech stocks have been beaten up mercilessly, so is now the time to buy?